While Alzheimer’s Disease (AD) treatment strategies have largely focussed on beta-amyloid and tau protein pathologies, the synapse itself may also be a critical endpoint to consider regarding disease modification. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.